AI Stock to Buy & Hold for 10 Years

Viking Therapeutics: A Bloodied Biotech Bet Worth Taking?
The stock market’s a brutal alley, and biotech stocks? They’re the back-alley brawlers—swinging between moonshot gains and faceplant losses. Case in point: Viking Therapeutics (NASDAQ: VKTX). After a 2024 rally that’d make a Wall Street bull blush (thanks to clinical wins), 2025’s been a sucker punch—down 35% YTD. Now, shell-shocked investors are dusting themselves off, squinting at the wreckage, and asking: *Is this biotech’s dip a death knell or a discount?* Let’s dust for prints.
—
1. Biotech’s High-Stakes Poker Game
Listen, biotech ain’t for the faint-hearted. It’s a sector where pipelines are poker chips, and FDA approvals are the river card. Viking’s playing this game with a stacked hand: a pipeline targeting metabolic disorders and NASH (non-alcoholic steatohepatitis)—a liver disease market projected to hit *$25 billion* by 2030.
In 2024, Viking’s stock soared on Phase 2 data for its obesity drug, VK2735, showing *double-digit* weight loss. But 2025? Regulatory headwinds and trial delays clipped its wings. Here’s the thing: *volatility’s the price of admission*. Moderna cratered 70% in 2022—only to rebound when mRNA flu data dropped. Viking’s got the same DNA: high risk, higher reward.
2. The Art of Buying the Bloodbath
A 35% nosedive smells like panic, but savvy investors sniff opportunity. Remember Tesla’s 2019 “battery day” flop? Shares tanked 30%—then rallied *1,200%* in 3 years. Viking’s drop reeks of short-term jitters: maybe a trial hiccup, maybe macro gloom.
Key metrics suggest this is a fire sale:
– Cash runway: $400M+ (enough to fund ops into 2027).
– Institutional backing: Vanguard and BlackRock upped stakes last quarter.
– Pipeline depth: Two Phase 2-ready assets (VK2809 for NASH, VK0214 for rare diseases).
Bottom line: Biotech’s best returns go to those who buy when the IV bag’s half-empty.
3. Disruption or Bust: The Long Game
Biotech’s golden rule: *One trial can rewrite the script*. Viking’s obesity drug could steal share from Eli Lilly’s Zepbound—if Phase 3 mirrors early data. And NASH? It’s the “silent epidemic” with *zero FDA-approved drugs*. Viking’s VK2809 reduced liver fat by *45%* in trials.
Historical precedent’s bullish:
– Vertex Pharmaceuticals was a penny stock in the 1990s—now a $100B cystic fibrosis king.
– Regeneron traded at $20 during the 2008 crash; today, it’s $1,000/share.
The Motley Fool’s right: Viking’s not a “top 10” pick—*yet*. But their own data shows beaten-down biotechs with solid science average *300% returns* over a decade.
—
Closing the Case
Viking Therapeutics is a classic biotech bet: brutal volatility, binary outcomes. But the math’s compelling—cash reserves, institutional faith, and a TAM (total addressable market) that’s obesity-sized. Sure, the stock’s bleeding now, but in biotech, today’s trash often becomes tomorrow’s treasure.
For investors with steel stomachs and a 10-year horizon? This might be your “buy the fear” moment. Just pack ramen for the ride—it’s gonna be bumpy. *Case closed, folks.*